Overview

A Study of Carboplatin, Cetuximab and RAD001 in Advanced Head and Neck Cancer

Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the drug RAD001 in combination with other chemotherapy drugs, Carboplatin and Cetuximab. Because RAD001 has not been used in this combination before, it is not clear which dose will be best when used in combination. The investigators will test the safety of RAD001 in combination with Carboplatin and Cetuximab and see what effects (good and/or bad) it has on your cancer, and find the highest dose of RAD001 that can be given without causing bad side effects. The doses of Carboplatin and Cetuximab will not be varied as both these drugs are considered to be part of the current standard of care for patients with your condition.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Emory University
Collaborator:
Novartis
Treatments:
Carboplatin
Cetuximab
Everolimus
Sirolimus